Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Cecchi

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Cancer Cell|August 18, 2012
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signalingFabiola Cecchi, Deborah Pajalunga, C Andrew Fowler, et al.
Investigational New Drugs|September 27, 2015
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
International Journal of Cancer|January 30, 2019
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancerOfra Novoplansky, Matthew Fury, Manu Prasad, et al.
Tumori|May 2, 2018
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plasticaLinda Mahjoubi, Fabiola Cecchi, Christophe Massard, et al.
Molecular Imaging|October 14, 2015
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled PeptideElaine M Jagoda, Sibaprasad Bhattacharyya, Joseph Kalen, et al.
Molecular Oncology|October 1, 2015
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapyPaolo Nuciforo, Sheeno Thyparambil, Claudia Aura, et al.
Cancer Discovery|February 17, 2018
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal AdenocarcinomaSteven B Maron, Lindsay Alpert, Heewon A Kwak, et al.
Ebiomedicine|November 30, 2020
High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapiesMaud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2012
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumabElaine M Jagoda, Lixin Lang, Veerendra Bhadrasetty, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Cancer Cell|August 18, 2012
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signalingFabiola Cecchi, Deborah Pajalunga, C Andrew Fowler, et al.
Investigational New Drugs|September 27, 2015
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumorsGeoffrey I Shapiro, Stewart McCallum, Laurel M Adams, et al.
International Journal of Cancer|January 30, 2019
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancerOfra Novoplansky, Matthew Fury, Manu Prasad, et al.
Tumori|May 2, 2018
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plasticaLinda Mahjoubi, Fabiola Cecchi, Christophe Massard, et al.
Molecular Imaging|October 14, 2015
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled PeptideElaine M Jagoda, Sibaprasad Bhattacharyya, Joseph Kalen, et al.
Molecular Oncology|October 1, 2015
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapyPaolo Nuciforo, Sheeno Thyparambil, Claudia Aura, et al.
Cancer Discovery|February 17, 2018
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal AdenocarcinomaSteven B Maron, Lindsay Alpert, Heewon A Kwak, et al.
Ebiomedicine|November 30, 2020
High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapiesMaud Toulmonde, Carlo Lucchesi, Stéphanie Verbeke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2012
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumabElaine M Jagoda, Lixin Lang, Veerendra Bhadrasetty, et al.
Pageof 5